Drug companies are moving up the value chain, transforming into complex generic manufacturers with high end R&D facilities.

While the Sensex hit an all-time high of 34,356, Nifty was trading above 10,600 for the first time ever, rising more than 50 points from Friday's close. Of 50 Nifty stocks, 45 were in trading the green.

 The just concluded year, hurt Indian pharma companies in more ways than one

Energy firms gained on higher crude prices as sentiment was upbeat in domestic and global energy stocks with Brent crude hitting its highest level since July 2015 after Saudi Arabia agreed to support the extension of a global oil production cut agreement. While Reliance Industries gained over 1 percent, the ONGC stock rose up to 4 per cent post its Q2 earnings.

The company which started its Indian operations in 2004 is going to launch some of its latest epilepsy and cancer drugs in India.

A number of Indian companies are facing action from the USFDA for failing manufacturing quality standards.

The post-Independence Indian pharma industry was really created by a generation of scientist-entrepreneurs who took advantage of the two changes made by the government in the 1970s.

Unlike many of the India Inc. successors who had got smoothly running companies on a platter, Habil Khorakiwala's younger son Murtaza faced a tough beginning.

A group of inheritors takes charge with new ideas and new strategies

India is home to world's fourth highest number of billionaires with Reliance Industries chief Mukesh Ambani leading the club of more than 100 super rich Indians, according to a new list released by Forbes magazine.

Warren Buffett talking about Ajit Jain, widely believed to be a strong contender to succeed the billionaire investor at Berkshire Hathaway, in his annual letter to shareholders.

Intra-day, it tumbled 6.67 per cent to Rs 701. On NSE, shares of the company dipped 4.84 per cent to close at Rs 713.65.

The Reserve Bank of India is expected to cut interest rates by 25 basis points at its policy review on Wednesday, a Reuters poll showed, after consumer inflation hit a two-year low in December, giving the central bank room to ease.

Torrent Pharmaceuticals was a late entrant to the US, but Samir Mehta has led it to fast-paced growth in that market.

Many global healthcare chains and investors are pumping money into hospitals in India. This may prove to be a game changer for the country's healthcare sector.

One of the earliest diagnoses made by Sun Pharma in the run-up to the Ranbaxy acquisition was that since the entire management was focusing on resolving the US FDA's negative observations, there was a lack of focus towards expanding the business.

From Ambanis and Adanis to Premjis and Khorakiwalas, several generation-next leaders of India's leading family-run businesses have joined crorepati club when it comes to their salaries and other perks.

Among losers, the Infosys stock fell as much as 3.25 per cent, Wockhardt and Jet Airways too closed lower on their Q1 earnings.

Drug firm Wockhardt on Saturday reported a fall of 82.65 per cent in consolidated net profit to Rs 15.89 crore for the first quarter ended June 30, mainly on account of dip in sales and increased expenditure.